文献速递介入胸部DSACT

评估8Spheres微球联合碘-125粒子治疗伴咯血的晚期肺鳞状细胞癌的疗效:一项回顾性研究

Evaluating the efficacy of 8Spheres microsphere combined with Iodine-125 seeds in the treatment of advanced lung squamous cell carcinoma presenting with hemoptysis: A retrospective study.
PubMed 文献 · Eur J Radiol · 2025-07-08

回顾性分析45例伴咯血的晚期肺鳞状细胞癌患者,采用8Spheres微球栓塞联合碘-125粒子植入,技术成功率100%,24小时内31例咯血完全缓解,其余咯血量减少超过70%,中位无咯血生存16个月、总生存15个月、无进展生存10个月,术后继续免疫治疗者生存指标显著改善,术前支气管动脉CTA可缩短手术时间。

要点

  • 8Spheres微球栓塞联合碘-125粒子植入治疗晚期肺鳞状细胞癌咯血,24小时内咯血完全缓解率与减少超过70%的比例需结合原文数值。
  • 术后继续免疫治疗者中位无咯血生存未达到 vs 10个月(P=0.008),中位总生存16个月 vs 11个月(P<0.001),中位无进展生存12个月 vs 7个月(P=0.003)。
  • 术前支气管动脉CTA可显著缩短手术时间(42.69±8.49 vs 64.81±7.55,P<0.05)。

核心结论

  • 8Spheres微球栓塞联合碘-125粒子植入是治疗晚期肺鳞状细胞癌咯血的有效且安全的方法,是受影响患者有前景的治疗选择;术前CTA检查可显著缩短手术时间,持续免疫治疗可能有助于延缓肿瘤进展。

研究设计与样本

  • 回顾性分析纳入45例诊断为晚期鳞状细胞癌并伴有咯血的患者,主要终点为栓塞后24小时内咯血控制率、无咯血生存和总生存,次要终点为无进展生存和并发症发生。

诊断标准与关键数值

  • 技术成功率为100%。
  • 8Spheres微球栓塞后24小时内,31例患者咯血完全缓解,其余患者咯血量减少超过70%。
  • 所有患者的中位无咯血生存为16个月,中位总生存为15个月,中位无进展生存为10个月。
  • 术后继续免疫治疗者中位无咯血生存未达到 vs 10个月(P=0.008),中位总生存16个月 vs 11个月(P<0.001),中位无进展生存12个月 vs 7个月(P=0.003)。
  • 使用术前支气管动脉CTA成像者手术时间42.69±8.49 vs 未使用者64.81±7.55(P<0.05)。

临床应用与阅片要点

  • 术前支气管动脉CTA成像可显著缩短手术时间(42.69±8.49 vs 64.81±7.55,P<0.05)。
  • 术后继续免疫治疗者中位无咯血生存、总生存和无进展生存均显著改善(P值分别为0.008、<0.001、0.003)。
  • 术后不良反应轻微,经对症治疗后消退。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Hemoptysis is a critical complication in advanced lung squamous cell carcinoma (LUSC). This study aims to evaluate the effectiveness and safety of 8Spheres microspheres embolization combined with iodine-125 seed implantation for managing hemoptysis in patients with advanced LUSC.

METHODS: A retrospective analysis was performed involving 45 patients diagnosed with advanced squamous cell carcinoma and experiencing hemoptysis. The primary endpoints included the control rate of hemoptysis within 24 h post-embolization, hemoptysis-free survival (HFS), and overall survival (OS). Secondary endpoints comprised progression-free survival (PFS) and the occurrence of complications.

RESULTS: The technical success rate was 100 %. Within 24 h following the 8Spheres microspheres embolization, hemoptysis was completely resolved in 31 patients, while the remaining patients showed a reduction of over 70 % in hemoptysis volume. The median HFS, median OS, and median PFS of all patients were 16 months, 15 months, and 10 months, respectively. Patients who continued with immunotherapy after the procedure demonstrated significant improvements in median HFS, median OS, and median PFS (median HFS: not reached vs. 10 months, P = 0.008; median OS: 16 months vs. 11 months, P < 0.001; median PFS: 12 months vs. 7 months, P = 0.003). The use of preoperative bronchial artery CTA imaging was shown to significantly decrease operative time (42.69 ± 8.49 vs. 64.81 ± 7.55, P < 0.05). Postoperative adverse reactions were mild and subsided with symptomatic treatment.

CONCLUSION: The combination of 8Spheres microspheres embolization and iodine-125 seed implantation is an effective and safe approach for managing hemoptysis in advanced lung squamous cell carcinoma, representing a promising therapeutic option for affected patients. Furthermore, preoperative CTA examination can significantly shorten operative time, while ongoing immunotherapy may help delay tumor progression.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ran L, Liang H, Chen J, et al. Evaluating the efficacy of 8Spheres microsphere combined with Iodine-125 seeds in the treatment of advanced lung squamous cell carcinoma presenting with hemoptysis: A retrospective study. Eur J Radiol. 2025. PMID: 40645027. doi:10.1016/j.ejrad.2025.112295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。